

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
**KATERINA LEFOTHERIS, ET AL.**  
APPLICATION NO: **10/696178**  
FILED: **10/29/2003**

ART UNIT: **1616**  
EXAMINER: **PRYOR, ALTON NATHANIEL**

FOR: **NP TITLE - METHODS OF TREATING P38 KINASE-ASSOCIATED  
CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE  
INHIBITORS**

**DIV TITLE - METHODS OF TREATING P38 KINASE-ASSOCIATED  
CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS**

**Filed via EFS**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

The reference was cited in a Foreign Office Action in a corresponding Indian application. A copy of the reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that the reference was considered by returning a copy of the initialed PTO 1449 form(s) and charge the appropriate fee under §1.17 (p) to Deposit Account 19-3880 in the name of Bristol-Myers Squibb Company.

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Date: January 31, 2007

/Joseph C. Wang/  
Joseph C. Wang  
Attorney for Applicant  
Reg. No. 44,391  
Phone: 609-252-4931